␣-Synuclein is a major component of the fibrillary lesion known as Lewy bodies and Lewy neurites that are the pathologic hallmarks of Parkinson's disease (PD). In addition, point mutations in the ␣-synuclein gene imply ␣-synuclein dysfunction in the pathology of inherited forms of PD. ␣-Synuclein is a member of a family of proteins found primarily in the brain and is concentrated within presynaptic terminals. Here, we address the localization and membrane binding characteristics of wild type and PD mutants of ␣-synuclein in cultured cells. In cells treated with high concentrations of fatty acids, wild type ␣-synuclein accumulated on phospholipid monolayers surrounding triglyceride-rich lipid droplets and was able to protect stored triglycerides from hydrolysis. PD mutant synucleins showed variable distributions on lipid droplets and were less effective in regulating triglyceride turnover. Chemical cross-linking demonstrated that synuclein formed small oligomers within cells, primarily dimers and trimers, that preferentially associated with lipid droplets and cell membranes. Our results suggest that the initial phases of synuclein aggregation may occur on the surfaces of membranes and that pathological conditions that induce cross-linking of synuclein may enhance the propensity for subsequent synuclein aggregation.
Parkinson's disease (PD)
1 is the most common neurodegenerative movement disorder, arising from the selective loss of dopaminergic neurons in the substantia nigra. In neurons that remain, abnormal filamentous aggregates called Lewy bodies and Lewy neurites serve as neuropathological hallmarks of the disease (1, 2) . Point mutations in the ␣-synuclein gene cause rare forms of autosomal-dominant familial PD (3, 4) , and wild type ␣-synuclein is a major component of the pathologic lesions characteristic of noninherited forms of PD (5) (6) (7) . In addition to PD, ␣-synuclein has also been found within intracellular inclusions from a diverse group of neurodegenerative disorders, thus implicating ␣-synuclein in the pathogenesis of an expanding spectrum of diseases characterized as ␣-synucleinopathies (8, 9) .
␣-Synuclein belongs to a family of small, structurally related proteins that are expressed predominantly in neural tissue and includes ␤-and ␥-synuclein, as well as the related protein synoretin (10 -13) . The expression and intracellular localization of ␣-and ␤-synuclein are similar; both proteins are expressed within the central nervous system and are concentrated within presynaptic terminals (11, 14 -17) . By contrast, ␥-synuclein is most abundant within the peripheral nervous system and is mainly cytosolic (18, 19) . Although ␣-and ␤-synuclein share considerable sequence similarity, only ␣-synuclein is found in the fibrillar lesions diagnostic of the synucleinopathies (9) .
All synuclein members share a common structural design, with the first two-thirds of the sequence organized within a series of amphipathic domains that may facilitate membrane binding (20 -22) . Purified synucleins are unfolded in solution (23) and yet adopt structures rich in ␣-helical character upon binding to synthetic lipid membranes containing acidic phospholipids (21, 24) . Whether synucleins display these same membrane-binding properties within living cells is not clear. For example, when ␣-synuclein is expressed in cultured cells, it displays a predominantly cytosolic distribution under normal conditions (25, 26) , although a close association between synuclein and membranes has been observed in the cell bodies of transfected neurons (27) . The ability of ␣-synuclein to associate with membranes destined for the neuronal synapse may therefore require specific lipid compositions or neuron-specific membrane-binding partners.
To investigate the membrane binding capacity of ␣-synuclein within cells, we examined the distribution of wild type and PD mutant synucleins in both immortalized cell lines and primary neuronal cultures. We found that in cells loaded with high concentrations of fatty acids, wild type synuclein redistributed from the cytosol to the surface of triglyceride-rich lipid droplets. The PD mutant synuclein A53T (3) also redistributed to lipid droplets, whereas the PD mutant A30P (4) remained cytosolic. Lipid droplets exist in a variety of cell types and consist of a core of neutral lipid (triglycerides and cholesterol esters) surrounded by a phospholipid monolayer originally derived from the endoplasmic reticulum (ER) (28, 29) . Their surfaces are covered with proteins including the perilipins in adipocytes and steroidogenic cells, and adipocyte differentiationrelated protein (ADRP) in other cells types (30, 31) . These proteins protect the core lipids from hydrolysis by soluble in-tracellular lipases (32, 33) . Similarly, we found that the binding of wild type synuclein to lipid droplet surfaces altered subsequent triglyceride metabolism, whereas the expression of PD mutant synucleins had little effect.
We also analyzed the conformation of ␣-synuclein from cells and cell extracts using a variety of cross-linking reagents. We found that ␣-synuclein exists mainly as small molecular weight oligomers (primarily dimers and trimers) that preferentially bound to cellular membranes. Our results suggest that the structural alterations that occur upon binding of ␣-synuclein to membranes may prime its oligomerization to form potentially toxic intermediates or progress into synuclein fibrils observed in brains of patients with various synucleinopathies.
EXPERIMENTAL PROCEDURES
Reagents-Human wild type as well as PD mutant synucleins were cloned into the expression vector pCDNA3.1 (Invitrogen, Carlsbad, CA). Human ␤-and ␥-synucleins were amplified by PCR from a brain cDNA library (CLONTECH, Palo Alto, CA) and cloned into the expression vector pTARGET (Promega, Madison, WI). Various chimeric synuclein molecules were generated by standard PCR techniques. For expression in bacteria, wild type and PD mutant synucleins were cloned into the NcoI-XhoI site of pET41a (Novagen, Madison, WI). To generate fulllength synucleins without the GST peptide, the vector was digested with NdeI-NcoI, blunt-ended, and religated by standard procedures. Proteins were expressed in BL21(DE3) bacteria and purified according to Jakes et al. (11) . Antibodies to synucleins included anti-␣-synuclein monoclonal antibodies 202 (used 1/100, (34), a kind gift from V. Lee, University of Pennsylvania), monoclonal LB509 (used 1/250, Zymed Laboratories Inc., South San Francisco, CA), polyclonal antisera to ␤-synuclein (used 1/500, Oncogene Research Products, Cambridge, MA), and polyclonal antisera to ␥-synuclein (used 1/500 Abcam Limited, Cambridge, UK). Monoclonal and polyclonal anti-calnexin antibodies (used 1/1000) were from Stressgen (Victoria, British Columbia, Canada). Monoclonal ADRP was from Research Diagnostics (used 1/10, for immunofluorescence, Flanders, NJ), and polyclonal anti-ADRP antibody (used 1/500, for immunoblotting) was a kind gift from Tom Keenan (Virginia Polytechnic Institute and State University, Blacksburg, VA). Alexa 488 and Alexa 598 species-specific secondary antibodies (used 1/500) were from Molecular Probes (Eugene, OR). The neutral lipid dye BODIPY 493/503 was from Molecular Probes. Oleic acid was from Calbiochem (San Diego, CA). [9, H(N)]oleic acid was from New England Nuclear (Boston, MA), and glycerol tri- [9, H(N)]oleate was from Amersham Biosciences, Inc. Triacsin C was from Biomol (Plymouth Meeting, PA). Silica gel G plates used for thin layer chromatography were from Analtech (Newark, DE). Cross-linking agents DSP, DMP, DMA, DTBP, and BS3 were from Pierce. Complete tablets (Roche Molecular Biochemicals) were used as a source of protease inhibitors. All other reagents were from Sigma. Semi-purified bovine hormone-sensitive lipase (HSL) was a kind gift from Dr. Carol Sztalryd (National Institutes of Health, Bethesda, MD).
Transfections, Lipid Loading, and Immunohistochemistry-All cell lines used in this study were cultured in Dulbecco's modified Eagle's medium (Invitrogen) with 10% fetal bovine serum, 2 mM glutamine, 100 units/ml penicillin, and 100 g/ml streptomycin and grown in a 5% CO 2 atmosphere at 37°C. Cells were transiently transfected either by using Fugene 6 (Roche Molecular Biochemicals) or by calcium phosphate precipitation. Stable 293 cell lines were selected in G418 but were routinely cultured following selection in its absence without loss of expression. Primary hippocampal neurons were dissociated from fetal rat brains and cultured as described (16) . The generation of transgenic mice expressing human wild type and A53T mutant synuclein will be described elsewhere. 2 For lipid loading, oleic acid was complexed to fatty acid-free bovine serum albumin (Sigma) at a ratio of 6 mol of oleic acid/mol of albumin according to Braselme et al. (33) and used at 300 M. Cells were incubated overnight to increase the synthesis and storage of triglyceride. Cells were fixed and processed for immunohistochemistry as described (35) . Lipid droplets were identified using the fluorescent neutral lipid dye BODIPY 493/503 (36) . Images were acquired on a Zeiss LSM 510 laser scanning confocal microscope, using either a 40ϫ Plan-Neofluor objective (NA 1.3) or a 100ϫ Plan-Apochromat objective (NA 1.4), and were processed as described (35) .
Lipid Analysis-Triglyceride turnover was measured according to Brasaemle et al. (33) . Briefly, control 293 cells or cells stably expressing wild type or PD mutant synucleins were plated into poly-D-lysine-coated 6-well dishes (Becton Dickinson Labware, Bedford, MA) and grown until subconfluent. 300 M [ 3 H]oleic acid (5 Ci/mmol, 1 Ci/well) complexed to fatty acid-free bovine serum albumin was added to cells in serum-containing medium for 16 h to generate a labeled pool of triglyceride. The medium was removed, and 6 M triacsin C (from a 1 mg/ml stock in Me 2 SO) was added in fresh culture medium without supplemental fatty acids to inhibit the reutilization of fatty acids released from hydrolyzed triglycerides (33, 37) . Cells were incubated for various periods of time, washed in phosphate-buffered saline (PBS) and harvested by gentle lifting of the cells from the dish into 1.5-ml polypropylene tubes. The cells were briefly pelleted at 800 ϫ g for 5 min, and the cell pellets were resuspended in 200 l of PBS and an aliquot taken for protein determination by BCA assay (Pierce). The remaining samples were placed into glass vials, and the cellular lipids were extracted and analyzed by thin layer chromatography (38) . Incorporation of radioactivity into triglycerides was determined by liquid scintillation counting (Beckman LS 6800) of silica gel bands containing triglycerides. Ci/reaction) and 0.6 mg of phospholipid (either phosphatidylcholine:phosphatidylinositol (3:1) or phosphatidylcholine alone), were mixed in a glass vial and evaporated using a gentle stream of nitrogen and processed according to Holm and Osterlund (39) . For experiments using gum arabic instead of phospholipids, the initial 2 ml of potassium phosphate was replaced by 2 ml of 5% gum arabic in 0.1 M potassium phosphate, pH 7.0, according to Khoo and Steinberg (40) . In experiments using recombinant synuclein, the substrate was preincubated for 15 min on ice with synuclein prior to adding semi-purified HSL. The extent of triolein hydrolysis was expressed as the number of nmol of free fatty acid released per hour.
Cross-linking-Cross-linking was performed either in intact cells or in post nuclear supernatants (PNS) from cells expressing the various synucleins. Cells were grown in 6-well dishes until confluent. Cells were rinsed with PBS, gently lifted from the dishes, and centrifuged at 800 ϫ g for 5 min to pellet the cells. Cells were resuspended in buffer A (20 mM HEPES, pH 7.4, 120 mM KCl, 2 mM EDTA, 2 mM EGTA, .25 M sucrose) containing protease inhibitors. For generation of a PNS, cells were broken by 12 passages through a 28-gauge syringe. Cells were centrifuged at 500 ϫ g for 10 min at 4°C to pellet intact cells and nuclei, and the supernatant was collected. Specific cross-linkers were added at various concentrations, and the cells or PNS were incubated for 1-3 h on ice. To terminate the cross-linking reaction, glycine was added (100 mM final concentration) and incubated for 15 min on ice. SDS sample buffer, with or without 100 mM dithiothreitol, was then added directly to the cross-linked samples. Samples were boiled for 5 min then loaded onto gels for SDS-PAGE.
Sucrose Gradient Centrifugation-To separate lipid droplets and total cell membranes from cytosol, postnuclear supernatants were prepared in buffer A as described above. The PNS was brought to 55% (w/v) sucrose (1.2 ml final) and overlaid with 2 ml of 45% (w/v) sucrose in buffer A and then with 2 ml of buffer A (8% sucrose). Centrifugation was performed in an SW55 rotor for 4.5 h at 265,000 ϫ g at 4°C. A tube slicer (Beckman Instruments) was used to collect lipid droplets that float to the tops of the tubes. Nine equivalent fractions were sequentially collected and analyzed by immunoblotting for the presence of synuclein as well as for organelle-specific markers. It was determined that the lipid droplet marker, ADRP, fractionated only to the top of the gradient (fraction 1), whereas the endoplasmic reticulum marker, calnexin (as well as markers for the Golgi complex, lysosomes, and plasma membrane), fractionated only to the 45/8% sucrose interface (fraction 4). Neither ADRP nor calnexin (nor other membrane markers) appeared in the cytosolic fraction (fraction 9). Thus we routinely collected and analyzed only fractions 1 (lipid droplets), 4 (total cell membranes), and 9 (cytosol). For the purification and concentration of lipid droplets, material from fraction 1 was brought to 20% sucrose and centrifuged at 14,000 ϫ g for 10 min. The infranatant was carefully removed and discarded. For the purification of total cell membranes, material collected from fraction 4 was diluted 4-fold in PBS and then pelleted through a 20% (w/v) sucrose-PBS cushion at 100,000 ϫ g for 30 min at 4°C in a TLA 100.4 rotor. Membranes were resuspended in buffer A for synuclein binding experiments.
RESULTS

Lipid Loading Induces the Reorganization of ␣-Synuclein
onto Intracellular Lipid Droplets-To investigate the specificity of ␣-synuclein/membrane interactions in cultured cells, we expressed wild type ␣-synuclein and the PD mutant synucleins A53T and A30P in HeLa cells. Wild type and PD mutant synucleins displayed primarily cytosolic distributions, although plasma membrane staining was often observed for wild type and A53T synucleins ( Fig. 1, a-c) . In some cells, staining for wild type and A53T synucleins also showed a ring-like appearance around phase dense structures that when labeled with the neutral lipid dye BODIPY493/503 were identified as intracellular lipid droplets (Fig. 1a, inset) . To confirm this identity, cells were incubated overnight with 300 M oleic acid. Under these conditions, free fatty acids are esterified and stored almost exclusively as triglyceride-rich lipid droplets (38) . Wild type and A53T synucleins showed a dramatic reorganization from the cytosol to the surfaces of the droplets, forming distinct rings around the core neutral lipid (Fig. 1, d and f). There was also an increase in reticular staining characteristic of the endoplasmic reticulum/nuclear envelope from which lipid droplets are derived (29) . The PD mutant A30P showed no lipid droplet binding (Fig. 1e) , consistent with previous results suggesting the A30P mutation reduces the ability of synuclein to bind membranes (41) . Approximately 30 -50% of transfected HeLa cells showed this reorganization upon lipid loading, whereas in transfected normal rat kidney (NRK) cells, this value was 80 -100%. Interestingly, a higher percentage of HeLa cells expressing A53T synuclein showed lipid droplet binding (ϳ40 -70%) compared with wild type, suggesting this PD mutant has a higher affinity for these lipid surfaces. The associations of the various synucleins with lipid droplets was independent of expression levels but could be saturated, resulting in additional cytosolic staining in highly expressing cells. Lipid droplet binding was conferred by the amphipathic domains of synuclein, since removal of the C-terminal 40 amino acids had no effect on its capacity to bind to lipid droplets (data not shown). In addition, appending an acidic FLAG epitope tag onto the N terminus of synuclein completely abrogated lipid droplet binding, whereas no effect was observed when FLAG was attached to the C terminus of synuclein (data not shown).
Primary hippocampal neurons from transgenic mice expressing wild type or A53T human synuclein also demonstrated this phenomenon ( Fig. 2A, left panel) , which mimicked the distribution of the ubiquitously expressed lipid droplet binding-protein, ADRP ( Fig. 2A, right panel) . Thus, although neurons generally do not accumulate high levels of triglycerides (42), wild type and A53T synucleins have the capacity to reorganize around lipid droplets in neurons under experimentally induced conditions. Interestingly, ␤-synuclein also bound to lipid droplets in lipid-loaded HeLa (and NRK) cells, whereas ␥-synuclein remained cytosolic (Fig. 2B) . This was not due to ␥-synuclein's shorter C terminus, since appending the C-terminal 14 amino acids of ␣-synuclein onto the C terminus of ␥-synuclein did not result in lipid droplet binding (data not shown).
Wild Type but Not PD Mutant Synucleins Protect Stored Triglycerides from Degradation-To assess what consequence, if any, synuclein binding may have on the metabolism of lipid droplets, HeLa cells were transfected with the various synuclein constructs and lipid-loaded as above. Cells were then washed free of the oleic acid and allowed to hydrolyze the stored triglyceride. After an overnight incubation in complete medium free of excess fatty acids, cells expressing wild type synuclein retained higher levels of neutral lipid staining than either of the PD mutants (Fig. 1, g-i) . This finding suggests that binding of wild type synuclein to the surface of lipid droplets reduces the hydrolysis of stored triglycerides, whereas both of the PD mutants, including the A53T mutant that binds to lipid droplets, cannot. Similarly, wild type human synuclein, but not the A53T mutant, protected lipid droplets from turnover in primary hippocampal neurons from transgenic mice (data not shown). Thus, the reduction of triglyceride turnover by wild type synuclein is not a particular property of transformed cells. Wild type synuclein apparently slowed but did not stop the rate of lipolysis, because all cells eventually metabolized their stored triglycerides. Interestingly, not all cells expressing wild type synuclein showed this protection.
To gain quantitative information on the effect of wild type and mutant synucleins on triglyceride metabolism, we gener- , arrowhead) . In some cells expressing wild type and A53T synuclein, rings of synuclein formed around triglyceride-rich lipid droplets (arrows in a and c), which is more evident upon higher magnification (a, inset). Note that A30P remains cytosolic (arrow in b). These phenotypes become more dramatic upon lipid loading (d-f). With lipid washout (g-i), wild type synuclein protects lipid droplets from turnover (g), whereas both PD mutants do not (h and i). Bar, 10 m.
to inhibit further triglyceride synthesis (33, 37) . At different times, lipids were extracted and triglyceride quantified (Fig.  3A) . Cells expressing wild type synuclein displayed higher initial levels of triglyceride after overnight labeling compared with PD mutant cell lines or control 293 cells. Both PD cells lines also showed a slight increase in the mass of stored triglyceride when compared with control cells. During the chase the amount of labeled triglyceride decreased with a t1 ⁄2 of 3 h in control cells, 4 -5 h in cells expressing the A30P and A53T mutants, and 10 h in wild type synuclein expressing cells. We observed no significant difference between control cells and cells expressing wild type or mutant synucleins in the initial uptake of fatty acids or their conversion into phospholipids or triglycerides (data not shown). Thus, the capacity to hydrolyze triglyceride is reduced in cells expressing wild type synuclein as compared with control cells or those expressing either of the PD mutants.
The relative inhibition of triglyceride turnover in cells expressing wild type synuclein could be due to enhanced protection of the lipid droplets from soluble neutral lipases or to a direct inhibition of the lipases themselves. To distinguish between these possibilities, we developed an in vitro assay that measures lipase activity through the release of free fatty acids from a labeled triglyceride substrate. Increasing amounts of recombinant synuclein were added to a reaction mixture that contained labeled triolein surrounded by a phospholipid monolayer to which purified HSL was added subsequently. As shown in Fig. 3B , addition of wild type synuclein inhibited release of free fatty acids (squares) up to 60% of the maximal release of triglycerides. Wild type synuclein had no effect on the rate of triolein hydrolysis in the absence of acidic phospholipids (crosses) or in the presence of a substrate emulsion that lacked a surface coating of phospholipid (diamonds). These results confirm observations that membrane binding of synuclein requires the presence of acidic phospholipids (21) . In addition, they suggest that synuclein does not directly inhibit HSL itself but may physically protect the substrate from enzyme access by binding to the surface phospholipid monolayer surrounding the neutral lipid substrate. Surprisingly, recombinant A53T was equally effective as wild type synuclein in blocking triolein hydrolysis (triangles) in vitro. This raises the possibility that additional cellular factors may be responsible for the differences between wild type and A53T synucleins in their effects on triglyceride turnover in intact cells. A significant lack of protection was observed with the PD mutant A30P (circles), consistent with its inability to bind lipid droplets within cells.
Synuclein Forms Oligomers within Cells-Purified ␣-synuclein is largely unfolded in solution but adopts a structure with strong ␣-helical character in the presence of membranes containing acidic phospholipids (21) . We reasoned that association with lipid droplets and other cellular membranes might be associated with structural alterations in ␣-synuclein, including the formation of oligomeric structures. Indeed, under certain conditions dimers, trimers, and higher molecular weight oligomers of synuclein have been observed (5, (43) (44) (45) , suggesting that transient interactions between synuclein monomers may become stabilized through various covalent mechanisms. We employed chemical cross-linking to investigate the oligomeric structure of synuclein within intact cells either in the presence or absence of lipid loading. Intact 293 cells that stably express wild type ␣-synuclein were treated with the membrane-permeable reducible cross-linker DTBP prior to quenching and analysis by nonreducing SDS-PAGE. Immunoblotting with anti-synuclein antibodies showed that in untreated cells synuclein was almost exclusively monomeric (Fig. 4A) . In the presence of DTBP, bands consistent with dimers and trimers were observed. Higher molecular weight bands were often seen, suggesting the formation of more complex oligomers, but these bands were less abundant (brackets in Fig. 4A ). We cannot rule out the possibility that additional proteins of similar size cross-linked to synuclein generate these additional bands, although similar results obtained with purified synuclein make it less likely (data not shown). Similar results were obtained from 293 cells stably expressing PD mutant synucleins, although the efficiencies of cross-linking between wild type and the PD mutants were not compared. In addition, synuclein from rat brain synaptosomes showed a similar cross-linking pattern (data not shown), demonstrating that this phenomenon is relevant to endogenous levels of synuclein. Other cross-linkers gave similar patterns, although the crosslinker DSP consistently produced a higher range of oligomers (tetramers, pentamers, etc.) than DTBP or the cross-linkers DMP or BS3. Synuclein self-association was not dependent on protein concentration because dilutions of post nuclear supernatants from cells expressing wild type synuclein had no effect on the capacity of synuclein to form oligomers (Fig. 4B) and occurred efficiently even when low concentrations of crosslinkers were used. However, we found that cross-linking was completely abrogated in the presence of non-ionic detergents (Fig. 4C ) but not ionic detergents (i.e. 0.1% SDS) (data not shown). These results raise the possibility that synuclein normally exists in cells as low molecular weight oligomers, primarily dimers and trimers, that are in equilibrium with monomeric synuclein and are stabilized by experimentally induced covalent association.
In the course of these experiments, we observed an unusual phenomenon regarding the reactivity of several anti ␣-synuclein antibodies. We observed that antibody reactivity to synuclein was enhanced in the presence of cross-linker, suggesting that epitopes were either formed or stabilized as a consequence of cross-linking (see "Discussion"). In addition, antibody reactivity was further enhanced when cross-linking was performed in lipid-loaded versus control cells, suggesting that synuclein oligomerization may be linked to increases in membrane and lipid droplet binding (data not shown; see Fig.  5 ). This increase in antibody reactivity was observed with a number of anti-synuclein antibodies, primarily those that recognize epitopes at the carboxyl terminus of the protein. Increasing amounts of recombinant wild type synuclein were added to an in vitro assay measuring triglyceride hydrolysis by purified HSL (see "Experimental Procedures"). Equivalent amounts of triolein substrate were surrounded by a phospholipid monolayer consisting of phosphatidylcholine:phosphatidylinositol (PC:PI; squares), phosphatidylcholine only (crosses), or a gum arabic emulsion lacking phospholipids (diamonds), and an equivalent quantity of wild type synuclein was added to each. Recombinant A53T (triangles) and A30P (circles) synuclein was incubated with PC:PI phospholipids. The results are expressed as nmol of fatty acid released/h. Results for A and B were determined from triplicate samples from two independent experiments and are expressed as the mean Ϯ S.D. Although the gum arabic and PC only experiments generated different levels of released fatty acids, no effect of synuclein was observed.
Synuclein Binding to Membranes Can Be Stabilized by
Cross-linking-␣-Synuclein is transported on membranes by both fast and slow axonal transport from the cell body to the neuronal synapse (46) . However, it does not bind tightly to synaptic membranes, and under most isolation conditions the majority of synuclein becomes cytosolic (15) (data not shown). Because we observed a change in the cellular distribution of ␣-synuclein with lipid loading, we investigated the membrane binding capacity of ␣-synuclein by cell fractionation under control and lipid-loaded conditions in the absence and presence of the cross-linker DSP. We found that under control conditions, ϳ20 -25% of wild type synuclein bound to membranes, including those containing the endoplasmic reticulum marker calnexin (Fig. 5A, lanes 2 and 3) . In lipid-loaded cells there was a reproducible increase in membrane binding (ϳ40% bound, lanes 5 and 6). Overexposure of the blot showed that a small percentage of synuclein stably bound to lipid droplets under these conditions (lane 4). Thus, wild type ␣-synuclein does not bind tightly to membranes or lipid droplets under normal conditions. The addition of DSP to the postnuclear supernatant prior to flotation did not significantly influence the capacity of synuclein to bind to membranes under control conditions (lanes 8 and 9) but did induce stable binding of synuclein to both membranes and lipid droplets under lipid-loaded conditions (lanes 10 -12) . As previously observed (see Fig. 4 ), there was a dramatic increase in antibody reactivity under lipid loading/ cross-linking conditions. Interestingly, synuclein oligomers fractionated primarily with lipid droplets and cell membranes under these conditions (lanes 10 -12) , suggesting that stabilized synuclein oligomers preferentially associated with cell membranes rather than in the cytosol.
The PD mutant A53T showed similar membrane binding properties as wild type synuclein, although the percentage of synuclein bound under normal and lipid-loaded conditions was slightly higher than wild type (Fig. 5, compare panel B, lanes 2  and 3 and 5 and 6, with panel A; data not shown) . The PD mutant A30P showed little membrane binding under normal conditions and only a slight increase in the capacity to bind membranes from lipid loaded cells (Fig. 5C , compare lanes 2 and 3 with 5 and 6). However, unlike wild type and A53T, A30P showed an increase in binding to membranes under crosslinking conditions (Fig. 5, compare panel C, lanes 5 and 8, with  panels A and B) . In addition, some binding of A30P to lipid droplets could be observed under lipid loaded/cross-linking conditions (Fig. 5C, lane 10) . This raises the possibility that A30P synuclein has the capacity to transiently bind to lipid droplets/ membranes, although less stably than wild type or A53T synuclein and that cross-linking stabilizes this interaction. Here, we show that ␣-synuclein (as well as ␤-synuclein but not ␥-synuclein) binds to the surface of triglyceride-rich lipid droplets in cultured cells as well as in primary neurons. Both wild type and the A53T mutant synucleins showed lipid droplet binding, whereas the A30P mutant remained primarily cytosolic. This is consistent with data demonstrating that the A30P mutation compromises (41) but does not eliminate (15, 22) membrane binding. In addition, wild type synuclein, but neither of the PD mutant synucleins, had the capacity to reduce the turnover of stored triglycerides within these droplets. Thus, although the A53T mutation does not prevent lipid droplet binding, it likely alters the conformation of the protein such that it is no longer as effective as wild type synuclein in reducing triglyceride hydrolysis. Results from an in vitro lipase assay suggest that this inhibition is likely due to the reduced accessibility of cytosolic lipases to the neutral lipid substrate rather than to direct inhibition of the lipase itself. In cells, Volumes loaded in each well were adjusted to give approximately equal protein concentrations. C, wild type synuclein was treated as described in A, either in the absence or presence of the indicated concentrations of Triton X-100. Note that in the presence of detergent, synuclein oligomer formation is completely prevented.
␣-synuclein reduced but did not completely block lipolysis and, consistent with flotation studies, this suggests that binding of synuclein to membranes is reversible (15) . Thus, synuclein appears to behave differently than lipid droplet-specific proteins involved in neutral lipid metabolism, such as ADRP and perilipin, which bind tightly to lipid droplet membranes in an apparently irreversible fashion (32, 33) . In addition, synuclein appears to act differently than perilipin in that its expression does not induce the accumulation of lipid droplets in the absence of lipid loading (33) . Why wild type synuclein and A53T synuclein behave differently within cells versus in vitro with regard to their capacity to protect triglycerides from hydrolysis is unclear. Possible explanations for this difference could be post-translational modifications of synuclein in vivo (47, 48) , differences in the precise composition of the membrane surrounding artificial versus in vivo lipid droplets, or the existence of cellular factors that influence the accessibility of lipases to lipid droplets and are not present in the in vitro assay.
The relevance of the lipid droplet binding properties of ␣-synuclein to its known association with synaptic membranes requires further explanation. The formation of lipid droplets is thought to occur between the luminal and cytoplasmic leaflets of the ER that either remain associated with the ER or pinch off to assume a cytosolic location (28, 29) . In either case, the neutral lipid core is surrounded by a phospholipid monolayer originally derived from ER membranes. Whether the phospholipid composition of lipid droplets differs substantially from parental ER membranes is not clear. In contrast, synaptic vesicles have aqueous contents surrounded by a phospholipid bilayer. However, the outer leaflet of both types of structures may be similar, whereas the requirement for the inner leaflet of a lipid bilayer in a synaptic vesicle may be dictated by its need to surround its aqueous contents. An expanding number of proteins, such as the caveolins and TIP47, are normally associated with other cellular membrane compartments but have been shown to localize to the surfaces of lipid droplets under certain conditions (28, 29, 49) . These surfaces may provide a favorable binding environment for cytosolic or non-bilayerspanning membrane proteins in which the binding properties are partially determined by hydrophobic interactions with membrane interiors. In this regard, the characteristics of synuclein binding to membranes appear similar to those of another peripheral synaptic protein, synapsin I. Binding of synapsin I to membranes requires acidic phospholipids (50) and induces an increase in its ␣-helical content (51) . In addition, synapsin I is able to penetrate into the hydrophobic core of lipid membranes (50) and, because of its high degree of surface activity, may coat a significant portion of the synaptic vesicle surface (52) . Thus, the binding of synuclein to lipid droplet monolayers as well as to synaptic membranes may be through initial electrostatic interactions with acidic phospholipids on membrane surfaces, with subsequent stabilization through binding to hydrophobic acyl chains supplied either by the underlying neutral lipid core (in the case of lipid droplets) or by the interior of the phospholipid bilayer itself (in the case of synaptic membranes). However, whereas synapsin I binding to synaptic vesicles is relatively stable (53) , binding of synuclein to lipid droplets/membranes appears to be more transient (Fig.  5) (15) . These observations are consistent with secondary structure predictions arising from comparison of the structure of synucleins with the lipid binding domains of the exchangeable apolipoproteins that bind via amphipathic ␣-helices (22) . If the initial binding of synuclein is via electrostatic interactions with acidic phospholipid head groups, the stabilization of lipid droplet/membrane binding of synuclein we observed under crosslinking conditions (see Fig. 5 ) may be due in part to covalent interactions generated between ⑀-amino groups of lysine residues on synuclein and primary amino groups on lipids such as phosphatidylethanolamine and phosphatidylserine. Consistent with this, synuclein has been shown to bind to both phosphatidylethanolamine and phosphatidylserine in brain lipid extracts (24) .
␣-Synuclein Forms Oligomers That Preferentially Bind Membranes-Chemical cross-linking experiments demonstrated that synuclein transiently self-associated to form primarily dimers and trimers, although higher order multimers were also detected. These various oligomeric species were formed even at low protein concentrations, and their generation was prevented in the presence of non-ionic detergents. These observations suggest that cross-linking stabilizes normal interactions between synuclein monomers specifically rather than bringing together randomly colliding molecules, and thus cross-linking FIG. 5 . Membrane binding properties of ␣-synuclein. 293 cells stably expressing wild type (A) or PD mutant (B and C) synucleins were untreated or lipid-loaded for 16 h. Postnuclear supernatants were generated and treated with or without 1 mM DSP for 2 h on ice and were then subjected to floatation on sucrose gradients (see "Experimental Procedures"). Fractions containing lipid droplets (fraction 1), total cell membranes (fraction 4), and cytosol (fraction 9) were collected and subjected to nonreducing SDS-PAGE followed by immunoblotting with antibodies to synuclein (202), the endoplasmic reticulum marker calnexin, or lipid droplets (ADRP). Note that synuclein oligomers preferentially associate with lipid droplet and membrane fractions. Also note the increase in antibody reactivity to synuclein in lipid-loaded crosslinked samples (lanes 10 -12) .
does not facilitate the formation of nonspecific low molecular weight aggregates.
The increases in antibody reactivity we observed upon crosslinking of synuclein was more dramatic when performed in cells and cell extracts than with purified synuclein, and reactivity was enhanced under conditions that resulted in higher proportions of membrane-bound synuclein (i.e. lipid loading). This was true for the monomer as well as oligomeric species. It is well established that membrane binding induces a dramatic conformational change in synuclein, with the amphipathic repeat regions forming ␣-helices associated with the membrane surface (21, 22) . This binding is predicted to be similar to class A2 apolipoproteins and would position positively charged lysine residues at the membrane/cytosol interface (20) . Crosslinking of membrane-bound synuclein may therefore stabilize its conformation resulting in the fixation of immunoreactive epitopes. Membrane binding also appears to increase the sensitivity of synuclein to cross-linking, and hence, oligomerization. Given that lipid loading increases the amount of synuclein bound to membranes/lipid droplets and results in more efficient formation of synuclein oligomers, our results are more consistent with the idea that the majority of synuclein oligomers are formed only after membrane binding and not by oligomers preformed in the cytosol that subsequently bind to membranes. This idea is compatible with a recent report suggesting that membrane-bound synuclein may generate nuclei that seed the formation of synuclein aggregates (54) . In addition, preliminary data suggest that preformed synuclein oligomers synthesized in vitro bind less well to native membranes than synuclein monomers (data not shown). Together with the discovery that synuclein-containing Lewy bodies purified from human PD brains contain lipids (55), our results raise the possibility that the initial phases of synuclein aggregation occur on membrane surfaces rather than in the cytosol, providing a potential explanation of the preferential fractionation of synuclein oligomers with membrane and lipid droplet components (Fig. 5, A-C) . In addition, we suggest that it is the generation of small synuclein oligomers, specifically dimers and trimers, that provides the source nuclei for further synuclein aggregation. What remains unclear is whether the membrane-bound oligomers that we observed here in the presence of synthetic cross-linking reagents retain the ␣-helical content of the synuclein monomer or adopt ␤-sheet-rich structures observed in so-called synuclein protofibrils (56) . If membrane binding is ultimately important in Lewy body formation, it is therefore likely that A53T, which binds more tightly to membranes (and lipid droplets) than wild type synuclein, and A30P, which binds significantly less well, cause PD by nonidentical mechanisms. It is yet unknown whether brains from patients with A30P mutations actually contain Lewy bodies.
In this study we have used synthetic cross-linking agents that react with free amino groups, primarily lysine residues. Under conditions of oxidative stress, similar cross-linked adducts may be formed in cells through the generation of lipid peroxidation-based cross-linking adducts (57, 58) between the numerous lysine residues positioned at the membrane/cytosol interface of membrane-bound synuclein (10, 54, 59) . Together with the generation of dityrosine cross-links (60) and through interactions with redox metals (43, 61) , the formation of synuclein oligomers may serve as a crucial nucleating mechanism for subsequent synuclein aggregation. Alternatively, these oligomers may themselves be the toxic species in PD. The data presented here suggest that synuclein bound to membrane surfaces may be particularly sensitive to these types of modifications, possibly because of the structural changes synuclein undergoes upon membrane binding. Naturally occurring cross-linking mechanisms would therefore be predicted to be critically important in synuclein oligomer formation and subsequent aggregation observed in the various synucleopathies.
